000119331 001__ 119331
000119331 005__ 20240228145433.0
000119331 0247_ $$2doi$$a10.2967/jnumed.116.179648
000119331 0247_ $$2pmid$$apmid:27660141
000119331 0247_ $$2ISSN$$a0022-3123
000119331 0247_ $$2ISSN$$a0097-9058
000119331 0247_ $$2ISSN$$a0161-5505
000119331 0247_ $$2ISSN$$a1535-5667
000119331 0247_ $$2ISSN$$a2159-662X
000119331 0247_ $$2altmetric$$aaltmetric:12190304
000119331 037__ $$aDKFZ-2017-00086
000119331 041__ $$aeng
000119331 082__ $$a610
000119331 1001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b0$$eFirst author
000119331 245__ $$aCorrelation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
000119331 260__ $$aNew York, NY$$bSoc.$$c2017
000119331 3367_ $$2DRIVER$$aarticle
000119331 3367_ $$2DataCite$$aOutput Types/Journal article
000119331 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660725487_9214
000119331 3367_ $$2BibTeX$$aARTICLE
000119331 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119331 3367_ $$00$$2EndNote$$aJournal Article
000119331 520__ $$aIn patients with lung cancer (LC), malignant melanoma (MM), gastroenteropancreatic neuroendocrine tumors (GEP NETs), and prostate cancer (PCA), lymph node (LN) staging is often performed by (18)F-FDG PET/CT (LC and MM), (68)Ga-DOTATOC PET/CT (GEP NET), and (68)Ga-labeled prostate-specific membrane antigen PET/CT (PCA) but is sometimes not accurate because of indeterminate PET findings. To better evaluate malignant LN infiltration, additional surrogate parameters, especially in cases with indeterminate PET findings, would be helpful. The purpose of this study was to evaluate whether SUVmax in the PET examination might correlate with semiautomated density measurements of LNs in the CT component of the PET/CT examination.After approval by the institutional review board, 1,022 LNs in the PET/CT examinations of 148 patients were retrospectively analyzed (LC: 327 LNs of 40 patients; MM: 224 LNs of 33 patients; GEP NET: 217 LNs of 35 patients; and PCA: 254 LNs of 40 patients). PET/CT was performed before surgery, biopsy, chemotherapy, or internal or external radiation therapy, according to the clinical schedule; patients with prior chemotherapy or radiation therapy were excluded. SUVmax analyses were based on uptake 60 min after tracer injection, and volumetric CT histogram analyses were based on the unenhanced CT images of the PET/CT scan.PET findings were considered positive or negative on the basis of SUVmax in the LN compared with that in the blood pool; histologic confirmation was not available. Of the 1,022 LNs, 331 were PET-positive (3 times the SUVmax of the blood pool), 86 were PET-indeterminate (1-3 times the SUVmax of the blood pool), and 605 were PET-negative (less than the SUVmax of the blood pool). PET-positive LNs had significantly higher CT densities than PET-negative LNs, irrespective of the type of cancer.CT density measurements of LNs in patients with LC, MM, GEP NET, and PCA correlated with(18)F-FDG uptake, (68)Ga-DOTATOC uptake, and (68)Ga-PSMA uptake, respectively, and might therefore serve as an additional surrogate parameter for differentiating between malignant and benign LNs. The use of a 7.5-Hounsfield unit CT density threshold to differentiate between malignant and benign LN infiltration and 20 Hounsfield units to exclude benign LN processes might be possible in clinical routine and would be especially helpful for PET-indeterminate LNs.
000119331 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000119331 588__ $$aDataset connected to CrossRef, PubMed,
000119331 7001_ $$aSchneider, Florian$$b1
000119331 7001_ $$aKratochwil, Clemens$$b2
000119331 7001_ $$aRath, Daniel$$b3
000119331 7001_ $$aMoltz, Jan$$b4
000119331 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b5
000119331 7001_ $$0P:(DE-He78)cdb6ba5e925fa050ebfa816181cf5769$$aKauczor, Hans-Ulrich$$b6
000119331 7001_ $$aSchwartz, Lawrence H$$b7
000119331 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b8
000119331 7001_ $$aFlechsig, Paul$$b9
000119331 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.179648$$gVol. 58, no. 2, p. 282 - 287$$n2$$p282 - 287$$tJournal of nuclear medicine$$v58$$x2159-662X$$y2017
000119331 909CO $$ooai:inrepo02.dkfz.de:119331$$pVDB
000119331 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119331 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119331 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)cdb6ba5e925fa050ebfa816181cf5769$$aExternal Institute$$b6$$kExtern
000119331 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000119331 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000119331 9141_ $$y2017
000119331 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2015
000119331 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119331 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119331 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119331 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119331 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119331 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119331 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119331 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119331 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119331 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119331 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2015
000119331 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000119331 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000119331 980__ $$ajournal
000119331 980__ $$aVDB
000119331 980__ $$aI:(DE-He78)E060-20160331
000119331 980__ $$aI:(DE-He78)C060-20160331
000119331 980__ $$aUNRESTRICTED